多重耐药鲍曼不动杆菌耐药机制及治疗策略的研究进展  

Research progress of drug-resistant mechanisms and treatment strategy of multi-drug resistant acinetobacter baumannii

作　　者：张鹏[1] 周燕斌[2] 黄炎明[1] 

机构地区：[1]广东省江门市中心医院重症医学科,广东江门529030 [2]中山大学附属第一医院呼吸内科,广东广州510080

出　　处：《中国医药科学》2014年第14期26-29,43,共5页China Medicine And Pharmacy

摘　　要：鲍曼不动杆菌已成为21世纪临床重要致病菌之一。鲍曼不动杆菌的耐药机制复杂,尤其是XDRAB和PDRAB,常对多种抗生素耐药,临床上治疗较困难,而且病死率高。目前最重要的是要合理选用抗生素,以减轻抗生素的选择性压力,避免多重耐药菌株的出现,控制耐药菌株的传播,同时监测各个地区间细菌的耐药性分析指导经验性治疗用药,对耐药菌的耐药机制做进一步深入研究。此文对近年来国内外多重耐药鲍曼不动杆菌的耐药机制、临床治疗策略及最新研究等方面作一综述。Acinetobacter baumannii has become one of the most important pathogens in clinical settings in the 21st century.The bacteria has a complex drug-resistant mechanisms. XDRAB and PDRAB,in particular,are resistant to a wide range of antibiotics.Clinical treatment to the bacteria is relatively difficult and related mortality rate remains high.The most important procedure is to properly select antibiotics so as to reduce selective pressure induced by antibiotics, avoid the occurrence of multi-drug resistant bacteria, and control the transmission of drug-resistant bacteria.At the same time,drug resistance of bacteria in different regions should be monitored,use of drugs in treatment should be analyzed and guided based on experience, and further researches should be carried out in terms of drug-resistant mechanisms of certain bacteria.This article provides an overview of drug-resistant mechanisms,clinical treatment strategy and latest researches of multi-drug resistant acinetobacter baumannii at home and abroad in recent years.

关 键 词：鲍曼氏不动杆菌 多重耐药 耐药性 耐药机制 治疗策略 

分 类 号：R446.5[医药卫生—诊断学]